REGENERON

Press Release

Regeneron Hires David Weinreich, M.D., M.B.A., as Senior Vice President, Late Stage Clinical Development and Medical Affairs

Tarrytown, New York (March 1, 2016) – Regeneron Pharmaceuticals, Inc. (NASDAQ: **REGN**) today announced that David Weinreich, M.D., M.B.A., has joined the company as Senior Vice President, Late Stage Clinical Development and Medical Affairs. Dr. Weinreich has more than 15 years of experience in drug development and was previously at Bayer Pharmaceuticals, where he served most recently as Senior Vice President and Head of Global Development for Specialty Medicine.

“David is a powerful addition to our leadership team at an important time for Regeneron, as we now have late-stage programs in six serious diseases and a robust R&D engine rapidly and consistently pushing even more candidates into the clinic,” said George D. Yancopoulos, M.D., Ph.D., Chief Scientific Officer of Regeneron and President of Regeneron Laboratories. “David’s medical training, capacity to devise thoughtful clinical programs and prior experience across multiple therapeutic areas will bolster our team’s ability to turn science into medicine for people in need.”

Dr. Weinreich will advise and aid collaboration between various therapeutic focus areas, Medical Affairs, and the Biostatistics and Data Management teams.

“Regeneron has an unmatched ability to advance entirely homegrown product candidates from the pipeline to people, applying their innovative mindset at every step,” said Dr. Weinreich. “I am thrilled to come onboard to help strengthen the company’s strategic clinical development capabilities at an exciting time of growth.”

Prior to Bayer, Dr. Weinreich held progressively senior roles in the oncology development organization at Amgen. Prior to Amgen, Dr. Weinreich served as Vice President of Clinical Affairs at Gene Logic and as an independent consultant helping small to mid-stage biotechnology companies with drug commercialization.

Dr. Weinreich received his undergraduate degree from Columbia University, his M.D. from Boston University, and his M.B.A. from the McDonough School of

REGENERON

Business at Georgetown University. He trained as a general surgeon at the University of Maryland, and completed fellowships in Surgical Oncology and Immunology from the National Cancer Institute.

About Regeneron Pharmaceuticals, Inc.
Regeneron (NASDAQ: REGN) is a leading science-based biopharmaceutical company based in Tarrytown, New York that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. Regeneron commercializes medicines for high LDL cholesterol, eye diseases, and a rare inflammatory condition and has product candidates in development in other areas of high unmet medical need, including oncology, rheumatoid arthritis, asthma, atopic dermatitis, pain and infectious diseases. For additional information about the company, please visit www.regeneron.com or follow @Regeneron on Twitter.

Forward-Looking Statements and Use of Digital Media
This press release includes forward-looking statements that involve risks and uncertainties relating to future events and the future performance of Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company"), and actual events or results may differ materially from these forward-looking statements. Words such as "anticipate," "expect," "intend," "plan," "believe," "seek," "estimate," variations of such words and similar expressions are intended to identify such forward-looking statements, although not all forward-looking statements contain these identifying words. These statements concern, and these risks and uncertainties include, among others, the nature, timing, and possible success and therapeutic applications of Regeneron's products, product candidates, and research and clinical programs now underway or planned; the extent to which the results from Regeneron's research programs or preclinical testing may lead to advancement of product candidates to clinical trials or therapeutic applications; unforeseen safety issues resulting from the administration of products and product candidates in patients, including serious complications or side effects in connection with the use of Regeneron's product candidates in clinical trials; the likelihood and timing of possible regulatory approval and commercial launch of Regeneron's late-stage product candidates and new indications for marketed products, including without limitation Praluent® (alirocumab) Injection, sarilumab, dupilumab, fasinumab and REGN2222; ongoing regulatory obligations and oversight impacting Regeneron's marketed products (such as EYLEA® (aflibercept) Injection and Praluent), research and clinical programs, and business, including those relating to patient privacy; determinations by regulatory and administrative governmental authorities which may delay or restrict Regeneron's ability to continue to develop or commercialize Regeneron's products and product candidates; competing drugs and product candidates that may be superior to Regeneron's products and product candidates; uncertainty of market acceptance and commercial success of Regeneron's products and product candidates and the impact of studies (whether conducted by Regeneron or others and whether mandated or voluntary), on the commercial success of Regeneron's products and product candidates; the ability of Regeneron to manufacture and manage supply chains for multiple products and product candidates; coverage and reimbursement determinations by third-party payers, including Medicare and Medicaid; unanticipated expenses; the costs of developing, producing, and selling products; the ability of Regeneron to meet any of its

REGENERON

sales or other financial projections or guidance and changes to the assumptions underlying those projections or guidance; the potential for any license or collaboration agreement, including Regeneron's agreements with Sanofi and Bayer HealthCare LLC, to be cancelled or terminated without any further product success; and risks associated with intellectual property of other parties and pending or future litigation relating thereto. A more complete description of these and other material risks can be found in Regeneron's filings with the U.S. Securities and Exchange Commission, including its Form 10-K for the fiscal year ended December 31, 2015. Any forward-looking statements are made based on management's current beliefs and judgment, and the reader is cautioned not to rely on any forward-looking statements made by Regeneron. Regeneron does not undertake any obligation to update publicly any forward-looking statement, including without limitation any financial projection or guidance, whether as a result of new information, future events, or otherwise.

Regeneron uses its media and investor relations website and social media outlets to publish important information about the Company, including information that may be deemed material to investors. Financial and other information about Regeneron is routinely posted and is accessible on Regeneron's media and investor relations website (http://newsroom.regeneron.com) and its Twitter feed (http://twitter.com/regeneron).

Your Media Contact at Regeneron:
Alexandra Bowie
914.847.3407
alexandra.bowie@regeneron.com